Conmed (NYSE:CNMD) is gearing up to announce its quarterly earnings on Wednesday, 2026-01-28. Here's a quick overview of what investors should know before the release.

Analysts are estimating that Conmed will report an earnings per share (EPS) of $1.32.

Conmed bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Overview of Past Earnings

Last quarter the company beat EPS by $0.03, which was followed by a 0.52% drop in the share price the next day.

Here's a look at Conmed's past performance and the resulting price change:

Market Performance of Conmed's Stock

Shares of Conmed were trading at $40.98 as of January 26. Over the last 52-week period, shares are down 44.0%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

Analyst Opinions on Conmed

Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Conmed.

Analysts have provided Conmed with 4 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $51.5, suggesting a potential 25.67% upside.

Peer Ratings Overview

This comparison focuses on the analyst ratings and average 1-year price targets of Enovis, Butterfly Network and Tandem Diabetes Care, three major players in the industry, shedding light on their relative performance expectations and market positioning.

• Analysts currently favor an Buy trajectory for Enovis, with an average 1-year price target of $44.5, suggesting a potential 8.59% upside.
• Analysts currently favor an Buy trajectory for Butterfly Network, with an average 1-year price target of $5.25, suggesting a potential 87.19% downside.
• Analysts currently favor an Neutral trajectory for Tandem Diabetes Care, with an average 1-year price target of $25.73, suggesting a potential 37.21% downside.

Insights: Peer Analysis

The peer analysis summary presents essential metrics for Enovis, Butterfly Network and Tandem Diabetes Care, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

Key Takeaway:

Conmed ranks in the middle for revenue growth among its peers. It has the highest gross profit margin. However, its return on equity is lower compared to its peers.

Discovering Conmed: A Closer Look

Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.

Conmed's Financial Performance

Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.

Revenue Growth: Conmed displayed positive results in 3 months. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 6.7%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 0.85%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.28%, the company showcases effective utilization of equity capital.

Return on Assets (ROA): Conmed's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.12% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: Conmed's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.85.

To track all earnings releases for Conmed visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.